20-216 - Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Status: openA Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)
Treatment for Non-Small Cell Lung Cancer (NSCLC)
Description
This study is looking at how pembrolizumab (pembro for short) with chemotherapy and radiation followed by pembro plus olaparib (or placebo for olaparib) works compared to chemotherapy and radiation followed by durvalumab in treating NSCLC that cannot be treated surgically and has not metastasized outside the chest in patients who have not received prior treatment for their cancer.
Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at (251) 445-9834 or by email at wlblount@health.southalabama.edu.
Providers Associated With This Trial
Principle Investigator
![Moh'd Khushman]()
View ProfileMoh'd Khushman, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology![Sachin Pai]()
View ProfileSachin Pai, M.D., M.S.C.I.Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical Oncology
